HomeCompareRGRX vs SCHD

RGRX vs SCHD: Dividend Comparison 2026

RGRX yields 666666.67% · SCHD yields 3.46%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 RGRX wins by $8.275235618773884e+34M in total portfolio value
10 years
RGRX
RGRX
● Live price
666666.67%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$8.275235618773884e+34M
Annual income
$82,727,945,429,218,320,000,000,000,000,000,000,000,000.00
Full RGRX calculator →
SCHD
Schwab U.S. Dividend Equity ETF
● Live price
3.46%
Share price
$30.48
Annual div
$1.06
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$29.0K
Annual income
$425.95
Full SCHD calculator →

Portfolio growth — RGRX vs SCHD

📍 RGRX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRGRXSCHD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RGRX + SCHD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RGRX pays
SCHD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RGRX
Annual income on $10K today (after 15% tax)
$56,666,666.67/yr
After 10yr DRIP, annual income (after tax)
$70,318,753,614,835,575,000,000,000,000,000,000,000,000.00/yr
SCHD
Annual income on $10K today (after 15% tax)
$294.40/yr
After 10yr DRIP, annual income (after tax)
$362.06/yr
At 15% tax rate, RGRX beats the other by $70,318,753,614,835,575,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RGRX + SCHD for your $10,000?

RGRX: 50%SCHD: 50%
100% SCHD50/50100% RGRX
Portfolio after 10yr
$4.137617809386942e+34M
Annual income
$41,363,972,714,609,160,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.97%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on RGRX right now

RGRX
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
-878.3
Piotroski
4/9
SCHD
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RGRX buys
0
SCHD buys
0
No recent congressional trades found for RGRX or SCHD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRGRXSCHD
Forward yield666666.67%3.46%
Annual dividend / share$2.00$1.06
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$8.275235618773884e+34M$29.0K
Annual income after 10y$82,727,945,429,218,320,000,000,000,000,000,000,000,000.00$425.95
Total dividends collected$8.275075881065991e+34M$3.9K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: RGRX vs SCHD ($10,000, DRIP)

YearRGRX PortfolioRGRX Income/yrSCHD PortfolioSCHD Income/yrGap
1← crossover$66,677,367$66,666,666.67$11,226$346.36+$66.67MRGRX
2$415,506,651,117$415,435,306,334.37$12,572$357.38+$415506.64MRGRX
3$2,419,908,598,386,268$2,419,464,006,269,573.00$14,046$367.84+$2419908598.37MRGRX
4$13,171,697,643,084,456,000$13,169,108,340,884,183,000.00$15,660$377.73+$13171697643084.44MRGRX
5$67,004,927,492,790,120,000,000$66,990,833,776,312,020,000,000.00$17,425$387.07+$67004927492790120.00MRGRX
6$318,562,277,003,514,840,000,000,000$318,490,581,731,097,560,000,000,000.00$19,354$395.86+$318562277003514871808.00MRGRX
7$1,415,484,168,853,553,000,000,000,000,000$1,415,143,307,217,159,200,000,000,000,000.00$21,461$404.13+$1.415484168853553e+24MRGRX
8$5,878,130,573,362,507,000,000,000,000,000,000$5,876,616,005,301,833,000,000,000,000,000,000.00$23,762$411.89+$5.878130573362507e+27MRGRX
9$22,813,793,009,840,743,000,000,000,000,000,000,000$22,807,503,410,127,248,000,000,000,000,000,000,000.00$26,272$419.15+$2.2813793009840744e+31MRGRX
10$82,752,356,187,738,840,000,000,000,000,000,000,000,000$82,727,945,429,218,320,000,000,000,000,000,000,000,000.00$29,010$425.95+$8.275235618773884e+34MRGRX

RGRX vs SCHD: Complete Analysis 2026

RGRXStock

RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapeutic peptide, thymosin beta 4, for tissue and organ protection, repair, and regeneration. The company is developing RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease, or other pathology; RGN-352, an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications; and RGN-137, a topical gel for dermal wounds and reduction of scar tissue. It has strategic partnerships with Lee's Pharmaceutical Group and GtreeBNT Co., Ltd. The company was formerly known as Alpha 1 Biomedicals, Inc. and changed its name to RegeneRx Biopharmaceuticals, Inc. in 2000. RegeneRx Biopharmaceuticals, Inc. was incorporated in 1982 and is based in Rockville, Maryland.

Full RGRX Calculator →

SCHDETF

The fund’s goal is to track as closely as possible, before fees and expenses, the total return of the Dow Jones U.S. Dividend 100 Index.

Full SCHD Calculator →
📬

Get this RGRX vs SCHD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RGRX vs JEPIRGRX vs ORGRX vs KORGRX vs MAINRGRX vs VYMRGRX vs DGRORGRX vs VIGRGRX vs HDV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.